Valuation: Pentixapharm Holding AG

Market Cap 56.51M 64.64M 51.93M 48.4M 91.81M 6.15B 93.2M 623M 242M 3.03B 243M 237M 10.42B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 56.51M 64.64M 51.93M 48.4M 91.81M 6.15B 93.2M 623M 242M 3.03B 243M 237M 10.42B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
55.19%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 64.67M
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+32.57%+24.89% 339B
-0.56%+0.96%+41.67%+39.35% 301B
-0.08%+1.30%+32.15%+44.48% 292B
-1.54%+2.81%-25.35%-39.61% 225B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.89%+4.87%+31.78%+58.22% 411.08B
Weighted average by Cap. +2.24%+5.69%+42.24%+83.14%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt - -
Logo Pentixapharm Holding AG
Pentixapharm Holding AG is a Germany-based clinical-stage radiopharmaceutical development company. The Company focuses on the development of radiopharmaceuticals for various therapeutic areas, as well as for the diagnosis and therapy (theranostics) of blood cancer and others. It is also engaged in holding activities and is also involved in the research and development of drugs for hematological and solid cancers, as well as cardiovascular, endocrine and inflammatory diseases.
Employees
36
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.280EUR
Average target price
12.61EUR
Spread / Average Target
+453.07%

Net sales - Rate of surprise